Home › Therapeutic areas › Oncology › Hepatocellular Carcinoma

Hepatocellular Carcinoma (10 companies)

Companies with an active program in Hepatocellular Carcinoma.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ADAG Adagene Oncology 1 Phase 2 $99.4M 10
CHRS Coherus Oncology Oncology 1 Approved $74.0M 5
CMPX Compass Therapeutics Oncology 1 Phase 2 $109M 15
CBIO Crescent Biopharma Oncology 1 Phase 2 $507M 10
EXEL Exelixis CardiovascularOncology 1 Approved $16.7B 23
MAIA MAIA Biotechnology Oncology 1 Phase 3 $77.2M 8
ONCY Oncolytics Biotech Oncology 1 Phase 2 $51.7M 4
REPL Replimune Group Oncology 1 Approved $1.87B 5
TYRA Tyra Biosciences MetabolicOncology Rare 1 Phase 2 $1.35B 5
ZYME Zymeworks OncologyRespiratory 1 Approved $1.78B 12